Skyrizi risankizumab composition of matter patent expiration date?

When does the “composition of matter” patent for Skyrizi (risankizumab) expire?

Skyrizi (risankizumab) is protected by at least one “composition of matter” (drug substance) patent tied to the active ingredient. The expiration date for that patent depends on the specific patent number and whether patent term adjustments or extensions apply.

DrugPatentWatch.com tracks risankizumab patent timelines and lists relevant “composition of matter” patents and their expected expiration dates here: DrugPatentWatch – Skyrizi (risankizumab) patents [1].

Which exact Skyrizi patent should you check for “composition of matter”?

“Composition of matter” protection usually maps to the patent that claims the molecular entity (the active ingredient), not the formulation or manufacturing process. To identify the right expiration date, check the specific patent listed as a composition-of-matter patent for risankizumab on DrugPatentWatch.com [1].

If you share the patent number you’re looking at (or a link to the specific record), I can help interpret what kind of protection it is and where the expiration date comes from.

Could exclusivity end later than the composition-of-matter patent?

Even after a composition-of-matter patent expires, other legal protections can delay market entry, including:
- Related patents covering methods of use or formulations
- Exclusivity not tied to a single patent (jurisdiction-dependent)

DrugPatentWatch.com focuses on patent-based protections and their timelines, so it’s useful for the composition-of-matter expiration date question, but you may also need to review the rest of the risankizumab patent estate for full “when generic/biosimilar can launch” timing [1].

How to use DrugPatentWatch to find the composition-of-matter expiration date quickly

On DrugPatentWatch’s risankizumab/Skyrizi page, look for the entry type that indicates “composition of matter” (or the molecular entity patent) and then read the listed “expiration date” for that patent record [1].

Sources

1. DrugPatentWatch – Skyrizi (risankizumab) patents